Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.43 |
| ▸ | MEF2D | Q14814 | 2/20 | 0.43 |
| ▸ | EP300 | Q09472 | 1/20 | 0.43 |
| ▸ | REN | P00797 | 4/20 | 0.43 |
| ▸ | CTSS | P25774 | 4/20 | 0.43 |
| ▸ | CTSK | P43235 | 3/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7416493 | 1.00 | AAK1 (0.53) | AAK1MAPTTP53HDAC4MEF2D | |
| SCHEMBL26304207 | 0.89 | AAK1 (0.54) | AAK1MAPTTP53RENCTSS | |
| SCHEMBL4080656 | 0.88 | AAK1 (0.55) | AAK1MAPTTP53HDAC4MEF2D | |
| SCHEMBL7413232 | 0.87 | MAPT (0.48) | AAK1MAPTTP53HDAC4REN | |
| SCHEMBL7413228 | 0.87 | MAPT (0.48) | AAK1MAPTTP53HDAC4REN | |
| SCHEMBL13165112 | 0.83 | HDAC8 (0.56) | HDAC4RENCTSSCTSKHDAC1 | |
| SCHEMBL20181226 | 0.83 | AAK1 (0.55) | AAK1MAPTTP53HDAC4MEF2D | |
| SCHEMBL13954255 | 0.81 | KDM4E (0.54) | TP53SMN1; SMN2 | |
| SCHEMBL1688818 | 0.81 | AAK1 (0.61) | AAK1MAPTTP53HDAC4CTSS | |
| SCHEMBL9286086 | 0.80 | AAK1 (0.51) | AAK1MAPTTP53CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6268378-B1 | TREATING AND PREVENTING OSTEOPOROSIS, AND INHIBITING VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, VIRAL DISEASE, AND TUMOR GROWTH. | MERCK & CO., INC. | 2001-07-31 | — | — | US | disclosed |
| EP-1040111-A1 | INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2000-10-04 | — | — | EP | disclosed |
| US-6066648-A | USEFUL IN INHIBITING BONE RESORPTION, TREATING AND PREVENTING OSTEOPOROSIS, AND INHIBITING VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, VIRAL DISEASE, AND TUMOR GROWTH | MERCK & CO., INC. (US) | 2000-05-23 | — | — | US | disclosed |
| US-6017926-A | Integrin receptor antagonists | MERCK & CO., INC. (US) | 2000-01-25 | — | — | US | disclosed |
| WO-1999031099-A1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1999-06-24 | — | — | WO | disclosed |